Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Choosing Wisely: Recommendations from Medical Specialties Beyond Rheumatology

Kurt Ullman  |  Issue: October 2014  |  October 1, 2014

“The one common theme that we saw in the ACR’s Choosing Wisely list and many other campaigns is imaging, imaging, imaging,” says Dr. King. “There are a variety of reasons for this overuse, including liability issues and patient expectations.”

It’s very clear, especially when talking about low back pain, that the use of imaging without red flags, including neurological deficits or the suspicion of other underlying processes such as infection, are not cost effective and can cause harm. The impact can be great, just because the number of patients is so large.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Low back pain is very common. About one in every four U.S. adults will have some experience with it over a three-month period, and rheumatologists are very likely to encounter it in clinical practice,” says Dr. Yazdany. “As many as half of all patients in some settings will receive imaging even though most guidelines recommend against it.”

Nuanced Decisions

Dr. Yazdany also notes that in many cases, the rheumatologist’s decision may not be quite as easy to make. Use of biologic or nonbiologic disease-modifying medications can increase the risk of infections in patients with rheumatic disease, and an immunocompromised state can sometimes be a red flag signaling that imaging may be appropriate.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“It is more likely that a patient seen by a rheumatologist may have the exceptions or red flags,” says Dr. Yazdany. “These lists are not to take the place of a clinical assessment and careful history and physical exam. When these concerns are found, appropriate imaging still needs to do be done.”

Dr. Saag
Dr. Saag

Another suggestion from the AAFP says that dual-energy X-ray absorptiometry (DEXA) should not be used to screen osteoporosis in women younger than 65 or men younger than 70 who have no risk factors. It is not viewed as a cost-effective test in younger, low-risk patients. However, the response to this may be more nuanced in rheumatology than in other specialty areas.

“The measure used by the AAFP is also consistent with what other national groups are considering,” says Ken Saag, MD, MSc, professor of medicine and director of the Center for Education & Research on Therapeutics of Musculoskeletal Disorders (CERTS) at the University of Alabama at Birmingham. “There are plenty of exceptions, and this is where this type of measure becomes challenging to the physician. We have a large number of people on corticosteroids, and they do need to be tested younger and more often.”

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:Drug UpdatesPractice SupportQuality Assurance/Improvement Tagged with:AC&RAmerican College of Rheumatology (ACR)BiologicscostsdrugimagingrheumatologistSafetyUllman

Related Articles

    Diagnostic Criteria Released for Neuromyelitis Optica Spectrum Disorders

    November 16, 2015

    Recent updates to criteria used for diagnosing neuromyelitis optica (NMO) are aimed at helping physicians make the differential diagnosis of this disorder differentiating it from other inflammatory disorders—a diagnosis that can be difficult given the presenting symptoms that can mimic a number of other conditions, such as multiple sclerosis. Published in July 2015, the new…

    Best Practices for Treating Non-Specific Low Back Pain

    December 16, 2015

    Low back pain (LBP) is one of the most common reasons for physician appointments. However, treatment results remain suboptimal, resulting in high rates of chronic pain, narcotic usage, surgery, depression and disability—all at great cost to individuals and the nation. One reason for this is the current practice of grouping all low back pain patients…

    Corona Borealis Studio / shutterstock.com

    The Reliability & Utility of Serological Antibody Tests in COVID-19

    September 11, 2020

    Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may play a critical role in the management of the worldwide health crisis. Such testing may reveal key information for epidemiology, convalescent plasma therapies and vaccine development. However, the situation is complex, and much is unknown. Although such testing may ultimately be used to…

    Serological Antibody Tests in COVID-19: Test Reliability and Utility

    June 10, 2020

    Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may play a critical role in the management of the worldwide health crisis. Such testing may reveal key information for epidemiology, convalescent plasma therapies and vaccine development. However, the situation is complex, and much is unknown. Although such testing may ultimately be used to…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences